On the public citation graph

SARS-CoV-2 Omicron Variant Neutralization in Serum from Vaccinated and Convalescent Persons

https://doi.org/10.1056/nejmc2119236

0 signed · 452 inferred · view as graph

Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.

Is this your work? Sign in with ORCID and put your name on the claims that are yours.

Claim with ORCID

Reference health. See whether every reference in this work resolves to a known work and none has been retracted — and get a dated CiteStamped badge you can embed.

See reference health

What this work says

Outgoing claims: the papers this work cites, builds on, or argues with.

inferredcites →https://doi.org/10.1038/d41586-021-03846-zopenalex-snapshot

Activity of convalescent and vaccine serum against SARS-CoV-2 Omicron

inferredcites →https://doi.org/10.1126/science.abn4947openalex-snapshot

Increased risk of SARS-CoV-2 reinfection associated with emergence of Omicron in South Africa

inferredcites →https://doi.org/10.3390/vaccines9010013openalex-snapshot

Comparison of Four SARS-CoV-2 Neutralization Assays

What points at this work

Incoming claims: where this work appears in other papers’ reference lists and arguments.

inferred← citeshttps://doi.org/10.2139/ssrn.4055646openalex-extracted

Protective Antibodies and T Cell Responses to Omicron Variant Three Months after the Booster Dose of BNT162b2 Vaccine

inferred← citeshttps://doi.org/10.2139/ssrn.4070419openalex-extracted

Antibody and T-Cell Responses 6 Months after Covid-19 mRNA-1273 Vaccination in Patients with Chronic Kidney Disease, on Dialysis, or Living with a Kidney Transplant

inferred← citeshttps://doi.org/10.2139/ssrn.4071508openalex-extracted

Effects of the Second Dose of COVID-19 Vaccines in Patients with Autoimmune Rheumatic Diseases with Hybrid Immunity

inferred← citeshttps://doi.org/10.2139/ssrn.4099431openalex-extracted

Safety and Cross-Reactive Immune Response Against the Omicron Variant of a Third Dose of CoronaVac, and Immune Persistence of Primary Immunization in Healthy Children and Adolescents: Interim Results from a Double-Blind, Randomised, Placebo-Controlled Phase 2 Clinical Trial

inferred← citeshttps://doi.org/10.2139/ssrn.4131160openalex-extracted

Severe Acute Respiratory Syndrome Corona Virus-2 (SARS-CoV-2) Serology in the Vaccination Era and Post Booster Vaccination

inferred← citeshttps://doi.org/10.2139/ssrn.4156654openalex-extracted

Severe Acute Respiratory Syndrome Corona Virus-2 (SARS-CoV-2) Serology in the Vaccination Era and Post Booster Vaccination

inferred← citeshttps://doi.org/10.2139/ssrn.4173050openalex-extracted

Durability of ChAdOx1 nCoV-19 (AZD1222) Vaccine and Hybrid Humoral Immunity Against Variants Including Omicron BA.1 and BA.4 Six Months after Vaccination: A Randomised, Phase 1b/2a Trial

inferred← citeshttps://doi.org/10.2139/ssrn.4190668openalex-extracted

Preclinial Safety and Efficacy of a Therapeutic Antibody That Targets SARS-CoV-2 at the Sotrovimab Face But is Escaped by Omicron

inferred← citeshttps://doi.org/10.2139/ssrn.4191606openalex-extracted

Titers and Capacity of Neutralizing Antibodies Against SARS-CoV-2 Variants after Heterologous Booster Vaccination in Health Care Workers Primed with Two Doses of ChadOx1 nCov-19: A Single-Blinded, Randomized Clinical Trial

inferred← citeshttps://doi.org/10.1001/jamanetworkopen.2022.12073openalex-snapshot

Neutralizing Antibodies Against the SARS-CoV-2 Omicron Variant (BA.1) 1 to 18 Weeks After the Second and Third Doses of the BNT162b2 mRNA Vaccine

inferred← citeshttps://doi.org/10.1001/jamanetworkopen.2022.32760openalex-snapshot

Estimated Effectiveness of COVID-19 Vaccines Against Omicron or Delta Symptomatic Infection and Severe Outcomes

inferred← citeshttps://doi.org/10.1002/14651858.cd014945.pub2openalex-snapshot

SARS-CoV-2-neutralising monoclonal antibodies to prevent COVID-19

inferred← citeshttps://doi.org/10.1002/adma.202200443openalex-snapshot

Rational Development of a Polysaccharide–Protein‐Conjugated Nanoparticle Vaccine Against SARS‐CoV‐2 Variants and Streptococcus pneumoniae

inferred← citeshttps://doi.org/10.1002/advs.202301034openalex-snapshot

A Mosaic Nanoparticle Vaccine Elicits Potent Mucosal Immune Response with Significant Cross‐Protection Activity against Multiple SARS‐CoV‐2 Sublineages

inferred← citeshttps://doi.org/10.1002/ajh.26746openalex-snapshot

Hyper‐inflammation and complement in COVID ‐19

inferred← citeshttps://doi.org/10.1002/ctd2.55openalex-snapshot

Preparedness for further boosting coronavirus disease 2019 vaccines

inferred← citeshttps://doi.org/10.1002/cti2.1424openalex-snapshot

Heterologous SARS‐CoV ‐2 IgA neutralising antibody responses in convalescent plasma

inferred← citeshttps://doi.org/10.1002/ctm2.1171openalex-snapshot

Impacts of delta and omicron variants on inactivated SARS‐CoV‐2 vaccine‐induced T cell responses in patients with autoimmune diseases and healthy controls

inferred← citeshttps://doi.org/10.1002/iid3.618openalex-snapshot

SARS‐CoV‐2 Omicron variant: Why global communities should take it seriously?

inferred← citeshttps://doi.org/10.1002/jmv.27560openalex-snapshot

Relative instantaneous reproduction number of Omicron SARS‐CoV‐2 variant with respect to the Delta variant in Denmark

inferred← citeshttps://doi.org/10.1002/jmv.27626openalex-snapshot

Emerging evidence on Omicron (B.1.1.529) SARS‐CoV‐2 variant

inferred← citeshttps://doi.org/10.1002/jmv.27633openalex-snapshot

Omicron (B.1.1.529) variant of SARS‐CoV‐2: Concerns, challenges, and recent updates

inferred← citeshttps://doi.org/10.1002/jmv.27749openalex-snapshot

“Is Omicron mild”? Testing this narrative with the mutational landscape of its three lineages and response to existing vaccines and therapeutic antibodies

inferred← citeshttps://doi.org/10.1002/jmv.28063openalex-snapshot

The long term vaccine‐induced anti‐SARS‐CoV‐2 immune response is impaired in quantity and quality under TNFα blockade

inferred← citeshttps://doi.org/10.1002/jmv.28275openalex-snapshot

Cartography of SARS‐CoV‐2 variants based on the susceptibility to therapeutic monoclonal antibodies

inferred← citeshttps://doi.org/10.1002/jmv.28308openalex-snapshot

Approaching COVID‐19 with epidemiological genomic surveillance and the sustainability of biodiversity informatics in Africa

inferred← citeshttps://doi.org/10.1002/jmv.29136openalex-snapshot

Reduced neutralization and Fc effector function to Omicron subvariants in sera from SARS‐CoV‐1 survivors after two doses of CoronaVac plus one dose subunit vaccine

inferred← citeshttps://doi.org/10.1002/mco2.172openalex-snapshot

Sub‐lineages of the SARS‐CoV‐2 Omicron variants: Characteristics and prevention

inferred← citeshttps://doi.org/10.1002/rmv.2358openalex-snapshot

Omicron – The new SARS‐CoV‐2 challenge?

inferred← citeshttps://doi.org/10.1002/rmv.2373openalex-snapshot

Recent insights into SARS‐CoV‐2 omicron variant

inferred← citeshttps://doi.org/10.1002/wnan.1823openalex-snapshot

Antiviral nanopharmaceuticals: Engineered surface interactions and virus‐selective activity

inferred← citeshttps://doi.org/10.1007/s00199-022-01468-8openalex-snapshot

Modelling optimal lockdowns with waning immunity

inferred← citeshttps://doi.org/10.1007/s00296-022-05265-3openalex-snapshot

Effects of the second dose of COVID-19 vaccines in patients with autoimmune rheumatic diseases with hybrid immunity

inferred← citeshttps://doi.org/10.1007/s11427-022-2207-7openalex-snapshot

A spike-trimer protein-based tetravalent COVID-19 vaccine elicits enhanced breadth of neutralization against SARS-CoV-2 Omicron subvariants and other variants

inferred← citeshttps://doi.org/10.1007/s11684-022-0954-xopenalex-snapshot

Neutralization against SARS-CoV-2 Delta/Omicron variants and B cell response after inactivated vaccination among COVID-19 convalescents

inferred← citeshttps://doi.org/10.1007/s42770-024-01387-xopenalex-snapshot

Enhancing the epidemiological surveillance of SARS-CoV-2 using Sanger sequencing to identify circulating variants and recombinants

inferred← citeshttps://doi.org/10.1007/s43538-023-00176-8openalex-snapshot

Exploratory analysis of SARS-CoV-2 omicron variant and its subvariant propagation: global predominance of BA.1*, BA.2*, BA.5*, BE.1*, and BQ.1*

inferred← citeshttps://doi.org/10.1016/b978-0-323-85730-7.00033-3openalex-snapshot

Gut microbiome and COVID-19

inferred← citeshttps://doi.org/10.1016/j.abb.2026.110861openalex-snapshot

Glycan shielding and epitope reorganization drive sotrovimab resistance in SARS-CoV-2 Omicron variants

inferred← citeshttps://doi.org/10.1016/j.ajem.2022.01.028openalex-snapshot

Clinical update on COVID-19 for the emergency clinician: Presentation and evaluation

inferred← citeshttps://doi.org/10.1016/j.artmed.2022.102427openalex-snapshot

COVID-DSNet: A novel deep convolutional neural network for detection of coronavirus (SARS-CoV-2) cases from CT and Chest X-Ray images

inferred← citeshttps://doi.org/10.1016/j.bbagen.2022.130288openalex-snapshot

Ferritin nanocages as efficient nanocarriers and promising platforms for COVID-19 and other vaccines development

inferred← citeshttps://doi.org/10.1016/j.biopha.2022.113977openalex-snapshot

Mutations in SARS-CoV-2: Insights on structure, variants, vaccines, and biomedical interventions

inferred← citeshttps://doi.org/10.1016/j.bj.2022.04.006openalex-snapshot

SARS-CoV-2 variants – Evolution, spike protein, and vaccines

inferred← citeshttps://doi.org/10.1016/j.bjid.2022.102703openalex-snapshot

COVID-19 and isolation: Risks and implications in the scenario of new variants

inferred← citeshttps://doi.org/10.1016/j.cell.2023.09.022openalex-snapshot

Population immunity predicts evolutionary trajectories of SARS-CoV-2

inferred← citeshttps://doi.org/10.1016/j.celrep.2022.111512openalex-snapshot

Reduced B cell antigenicity of Omicron lowers host serologic response

inferred← citeshttps://doi.org/10.1016/j.chom.2022.01.005openalex-snapshot

SARS-CoV-2 prolonged infection during advanced HIV disease evolves extensive immune escape

inferred← citeshttps://doi.org/10.1016/j.chom.2022.04.017openalex-snapshot

SARS-CoV-2 Omicron sublineages show comparable cell entry but differential neutralization by therapeutic antibodies

inferred← citeshttps://doi.org/10.1016/j.chom.2023.07.004openalex-snapshot

Rational design of a booster vaccine against COVID-19 based on antigenic distance

inferred← citeshttps://doi.org/10.1016/j.cmi.2022.04.019openalex-snapshot

Heterologous ChAdOx1 and Bnt162b2 vaccination induces strong neutralizing antibody responses against SARS-CoV-2 including delta variant with tolerable reactogenicity

inferred← citeshttps://doi.org/10.1016/j.coviro.2023.101349openalex-snapshot

Antigenic evolution of SARS coronavirus 2

inferred← citeshttps://doi.org/10.1016/j.crmicr.2022.100158openalex-snapshot

Methylene blue, Mycophenolic acid, Posaconazole, and Niclosamide inhibit SARS-CoV-2 Omicron variant BA.1 infection of human airway epithelial organoids

inferred← citeshttps://doi.org/10.1016/j.ebiom.2022.103938openalex-snapshot

Sub-optimal neutralisation of omicron (B.1.1.529) variant by antibodies induced by vaccine alone or SARS-CoV-2 Infection plus vaccine (hybrid immunity) post 6-months

inferred← citeshttps://doi.org/10.1016/j.ebiom.2022.103986openalex-snapshot

Boosting of serum neutralizing activity against the Omicron variant among recovered COVID-19 patients by BNT162b2 and CoronaVac vaccines

inferred← citeshttps://doi.org/10.1016/j.ebiom.2022.103997openalex-snapshot

Pathogenicity of SARS-CoV-2 Omicron (R346K) variant in Syrian hamsters and its cross-neutralization with different variants of concern

inferred← citeshttps://doi.org/10.1016/j.ebiom.2022.104008openalex-snapshot

The displacement of the SARS-CoV-2 variant Delta with Omicron: An investigation of hospital admissions and upper respiratory viral loads

inferred← citeshttps://doi.org/10.1016/j.ebiom.2022.104062openalex-snapshot

Design, immunogenicity, and efficacy of a pan-sarbecovirus dendritic-cell targeting vaccine

inferred← citeshttps://doi.org/10.1016/j.ebiom.2022.104073openalex-snapshot

Heterologous ChAdOx1/BNT162b2 vaccination induces stronger immune response than homologous ChAdOx1 vaccination: The pragmatic, multi-center, three-arm, partially randomized HEVACC trial

inferred← citeshttps://doi.org/10.1016/j.ebiom.2022.104158openalex-snapshot

Limited neutralisation of the SARS-CoV-2 Omicron subvariants BA.1 and BA.2 by convalescent and vaccine serum and monoclonal antibodies

inferred← citeshttps://doi.org/10.1016/j.ebiom.2022.104196openalex-snapshot

Replicating RNA platform enables rapid response to the SARS-CoV-2 Omicron variant and elicits enhanced protection in naïve hamsters compared to ancestral vaccine

inferred← citeshttps://doi.org/10.1016/j.eclinm.2022.101576openalex-snapshot

Neutralising antibody responses to SARS-CoV-2 omicron among elderly nursing home residents following a booster dose of BNT162b2 vaccine: A community-based, prospective, longitudinal cohort study

inferred← citeshttps://doi.org/10.1016/j.envres.2022.112816openalex-snapshot

Emergence of SARS-CoV-2 Omicron (B.1.1.529) variant, salient features, high global health concerns and strategies to counter it amid ongoing COVID-19 pandemic

inferred← citeshttps://doi.org/10.1016/j.envres.2022.112911openalex-snapshot

SARS-CoV-2 Reinfections: Overview of Efficacy and Duration of Natural and Hybrid Immunity

inferred← citeshttps://doi.org/10.1016/j.envres.2023.115612openalex-snapshot

The spread of the omicron variant: Identification of knowledge gaps, virus diffusion modelling, and future research needs

inferred← citeshttps://doi.org/10.1016/j.heliyon.2023.e13285openalex-snapshot

Insight into SARS-CoV-2 Omicron variant immune escape possibility and variant independent potential therapeutic opportunities

inferred← citeshttps://doi.org/10.1016/j.heliyon.2023.e16750openalex-snapshot

Changes within the P681 residue of spike dictate cell fusion and syncytia formation of Delta and Omicron variants of SARS-CoV-2 with no effects on neutralization or infectivity

inferred← citeshttps://doi.org/10.1016/j.hlife.2023.07.002openalex-snapshot

Distinctive serotypes of SARS-related coronaviruses defined by convalescent sera from unvaccinated individuals

inferred← citeshttps://doi.org/10.1016/j.ijid.2022.07.005openalex-snapshot

Clinical characteristics of the Omicron variant - results from a Nationwide Symptoms Survey in the Faroe Islands

inferred← citeshttps://doi.org/10.1016/j.ijid.2022.12.008openalex-snapshot

Long-term outcomes of COVID-19 convalescents: An 18.5-month longitudinal study in Wuhan

inferred← citeshttps://doi.org/10.1016/j.ijid.2023.01.023openalex-snapshot

Neutralizing antibodies after three doses of the BNT162b2 vaccine, breakthrough infection, and symptoms during the Omicron-predominant wave

inferred← citeshttps://doi.org/10.1016/j.imlet.2022.09.001openalex-snapshot

Full seroconversion in initial non-responders with higher antibody levels after heterologous COVID-19 vaccination schedule.

inferred← citeshttps://doi.org/10.1016/j.immuni.2022.04.003openalex-snapshot

Analysis of memory B cells identifies conserved neutralizing epitopes on the N-terminal domain of variant SARS-Cov-2 spike proteins

inferred← citeshttps://doi.org/10.1016/j.immuni.2022.05.018openalex-snapshot

The magnitude and timing of recalled immunity after breakthrough infection is shaped by SARS-CoV-2 variants

inferred← citeshttps://doi.org/10.1016/j.immuni.2022.07.018openalex-snapshot

Antigenic cartography using sera from sequence-confirmed SARS-CoV-2 variants of concern infections reveals antigenic divergence of Omicron

inferred← citeshttps://doi.org/10.1016/j.isci.2022.104076openalex-snapshot

Omicron’s binding to sotrovimab, casirivimab, imdevimab, CR3022, and sera from previously infected or vaccinated individuals

inferred← citeshttps://doi.org/10.1016/j.isci.2022.104719openalex-snapshot

Vaccination with a bacterial peptide conjugated to SARS-CoV-2 receptor-binding domain accelerates immunity and protects against COVID-19

inferred← citeshttps://doi.org/10.1016/j.isci.2022.104935openalex-snapshot

Anti-human ACE2 antibody neutralizes and inhibits virus production of SARS-CoV-2 variants of concern

inferred← citeshttps://doi.org/10.1016/j.isci.2022.105649openalex-snapshot

Co-display of diverse spike proteins on nanoparticles broadens sarbecovirus neutralizing antibody responses

inferred← citeshttps://doi.org/10.1016/j.isci.2023.105949openalex-snapshot

An inactivated SARS-CoV-2 vaccine induced cross-neutralizing persisting antibodies and protected against challenge in small animals

inferred← citeshttps://doi.org/10.1016/j.isci.2023.106323openalex-snapshot

Preclinical safety and efficacy of a therapeutic antibody that targets SARS-CoV-2 at the sotrovimab face but is escaped by Omicron

inferred← citeshttps://doi.org/10.1016/j.isci.2023.106457openalex-snapshot

Impact of hybrid immunity booster vaccination and Omicron breakthrough infection on SARS-CoV-2 VOCs cross-neutralization

inferred← citeshttps://doi.org/10.1016/j.isci.2023.107554openalex-snapshot

Explicit modeling of antibody levels for infectious disease simulations in the context of SARS-CoV-2

inferred← citeshttps://doi.org/10.1016/j.jconrel.2024.01.002openalex-snapshot

An inoculation site-retained mRNA vaccine induces robust immune responses against SARS-CoV-2 variants

inferred← citeshttps://doi.org/10.1016/j.jcv.2022.105191openalex-snapshot

A qualitative RT-PCR assay for the specific identification of the SARS-CoV-2 B.1.1.529 (Omicron) Variant of Concern

inferred← citeshttps://doi.org/10.1016/j.jcv.2022.105328openalex-snapshot

Titers and breadth of neutralizing antibodies against SARS-CoV-2 variants after heterologous booster vaccination in health care workers primed with two doses of ChAdOx1 nCov-19: A single-blinded, randomized clinical trial

inferred← citeshttps://doi.org/10.1016/j.jcvp.2022.100130openalex-snapshot

Severe acute respiratory syndrome corona virus-2 (SARS-CoV-2) serology in the vaccination era and post booster vaccination

inferred← citeshttps://doi.org/10.1016/j.jfma.2022.11.015openalex-snapshot

Evolution of neutralizing antibodies and cross-activity against different variants of SARS-CoV-2 in patients recovering from COVID-19

inferred← citeshttps://doi.org/10.1016/j.jiac.2024.02.015openalex-snapshot

Ensitrelvir in patients with SARS-CoV-2: A retrospective chart review

inferred← citeshttps://doi.org/10.1016/j.jinf.2022.02.005openalex-snapshot

Substantial immune response in Omicron infected breakthrough and unvaccinated individuals against SARS-CoV-2 variants of concern

inferred← citeshttps://doi.org/10.1016/j.jinf.2022.02.009openalex-snapshot

Assessment 2 months after the administration of a 3rd dose mRNA: a new variant-adapted vaccine is expected

inferred← citeshttps://doi.org/10.1016/j.jinf.2022.03.016openalex-snapshot

Elevated neutralization of Omicron with sera of COVID-19 recovered and breakthrough cases vaccinated with Covaxin than two dose naïve vaccinees

inferred← citeshttps://doi.org/10.1016/j.jinf.2022.04.018openalex-snapshot

Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial.

inferred← citeshttps://doi.org/10.1016/j.jinf.2022.04.021openalex-snapshot

Cohorting inpatients with Omicron and Delta variants of Sars-CoV-2 does not increase rates of mixed infection

inferred← citeshttps://doi.org/10.1016/j.jinf.2022.04.031openalex-snapshot

Reduced neutralizing antibody response in naïve Covishield vaccinees against Omicron emphasizes booster vaccination

inferred← citeshttps://doi.org/10.1016/j.jinf.2024.106121openalex-snapshot

Molecular insights into the adaptive evolution of SARS-CoV-2 spike protein

inferred← citeshttps://doi.org/10.1016/j.jmii.2024.02.004openalex-snapshot

Effectiveness and evolution of anti-SARS-CoV-2 spike protein titers after three doses of COVID-19 vaccination in people with HIV

inferred← citeshttps://doi.org/10.1016/j.jtbi.2022.111296openalex-snapshot

Analysis of serological surveys of antibodies to SARS-CoV-2 in the United States to estimate parameters needed for transmission modeling and to evaluate and improve the accuracy of predictions

inferred← citeshttps://doi.org/10.1016/j.jvacx.2023.100334openalex-snapshot

Long-term immunogenicity in previously vaccinated healthcare workers with inactivated virus vaccine after SARS-CoV-2 infection or booster vaccination

inferred← citeshttps://doi.org/10.1016/j.jvacx.2024.100538openalex-snapshot

Safety and antibody responses of Omicron BA.4/5 bivalent booster vaccine among hybrid immunity with diverse vaccination histories: A cohort study

inferred← citeshttps://doi.org/10.1016/j.jvacx.2025.100698openalex-snapshot

A phase II/III, randomized, double-blind, placebo-controlled trial to evaluate immunogenicity and safety of the Gam-COVID-Vac combined vector vaccine in the prophylactic treatment for SARS-СoV-2 infection in the United Arab Emirates

inferred← citeshttps://doi.org/10.1016/j.lanmic.2026.101500openalex-snapshot

Assessing SARS-CoV-2 immune markers in vaccinated asymptomatic adults after household exposure in Canada (AB-PROTECT): a prospective cohort study

inferred← citeshttps://doi.org/10.1016/j.mcpro.2023.100537openalex-snapshot

SARS-CoV-2 Variants Show Different Host Cell Proteome Profiles With Delayed Immune Response Activation in Omicron-Infected Cells

inferred← citeshttps://doi.org/10.1016/j.medj.2022.04.002openalex-snapshot

Immunogenicity of convalescent and vaccinated sera against clinical isolates of ancestral SARS-CoV-2, Beta, Delta, and Omicron variants

inferred← citeshttps://doi.org/10.1016/j.medj.2022.09.001openalex-snapshot

Omicron neutralizing antibody response following booster vaccination compared with breakthrough infection

inferred← citeshttps://doi.org/10.1016/j.micres.2022.126993openalex-snapshot

Application of pseudovirus system in the development of vaccine, antiviral-drugs, and neutralizing antibodies

inferred← citeshttps://doi.org/10.1016/j.onehlt.2025.101145openalex-snapshot

Cross-neutralization of human sera with diverse SARS-CoV-2 omicron exposure histories, 2022–2024: Evidence of immune heterogeneity

inferred← citeshttps://doi.org/10.1016/j.phymed.2023.154942openalex-snapshot

Kaempferol inhibits SARS-CoV-2 invasion by impairing heptad repeats-mediated viral fusion

inferred← citeshttps://doi.org/10.1016/j.procbio.2023.01.018openalex-snapshot

Convalescent plasma (hyperimmune immunoglobulin) for COVID-19 management: An update

inferred← citeshttps://doi.org/10.1016/j.scitotenv.2022.157375openalex-snapshot

Wastewater surveillance allows early detection of SARS-CoV-2 omicron in North Rhine-Westphalia, Germany

inferred← citeshttps://doi.org/10.1016/j.transproceed.2023.02.034openalex-snapshot

Low Performance of Sinovac Vaccine Particularly With Belatacept Therapy in a Study With Different Types of COVID-19 Vaccines in Transplanted Patients

inferred← citeshttps://doi.org/10.1016/j.vaccine.2022.04.072openalex-snapshot

Response to letter to the editor: Immunophenotyping of SARS-CoV-2 and vaccine design

inferred← citeshttps://doi.org/10.1016/j.vaccine.2022.07.006openalex-snapshot

Humoral and cellular responses to SARS-CoV-2 BNT162b2 vaccination in allogeneic hematopoietic stem cell transplantation recipients

inferred← citeshttps://doi.org/10.1016/j.vaccine.2022.07.013openalex-snapshot

Skin-patch delivered subunit vaccine induces broadly neutralising antibodies against SARS-CoV-2 variants of concern

inferred← citeshttps://doi.org/10.1016/j.vaccine.2023.02.062openalex-snapshot

Vaccine effectiveness and duration of protection of COVID-19 mRNA vaccines against Delta and Omicron BA.1 symptomatic and severe COVID-19 outcomes in adults aged 50 years and over in France

inferred← citeshttps://doi.org/10.1016/j.vaccine.2023.03.056openalex-snapshot

Safety and immunogenicity of heterologous ChAdOx1-nCoV19 and BNT162b2 vaccination: A meta-analysis of the heterologous COVID-19 vaccination outcomes

inferred← citeshttps://doi.org/10.1016/j.vaccine.2025.126989openalex-snapshot

Targeting the early life stages of SARS-CoV-2 using a multi-peptide conjugate vaccine

inferred← citeshttps://doi.org/10.1016/j.vaccine.2025.127459openalex-snapshot

Exposure to two antigenically distinct SARS-CoV-2 variants broadens neutralization patterns

inferred← citeshttps://doi.org/10.1016/j.virol.2022.01.011openalex-snapshot

Analysis of SARS-CoV-2 synonymous codon usage evolution throughout the COVID-19 pandemic

inferred← citeshttps://doi.org/10.1016/j.virs.2022.11.007openalex-snapshot

The humoral and cellular immune evasion of SARS-CoV-2 Omicron and sub-lineages

inferred← citeshttps://doi.org/10.1016/j.virusres.2022.198907openalex-snapshot

Genomic and epidemiologic surveillance of SARS-CoV-2 in Southern Brazil and identification of a new Omicron-L452R sublineage

inferred← citeshttps://doi.org/10.1016/j.virusres.2023.199131openalex-snapshot

SARS-CoV-2 omicron BA.1.1 is highly resistant to antibody neutralization of convalescent serum from the origin strain

inferred← citeshttps://doi.org/10.1016/j.xcrm.2022.100716openalex-snapshot

Protective antibodies and T cell responses to Omicron variant after the booster dose of BNT162b2 vaccine

inferred← citeshttps://doi.org/10.1016/j.xcrm.2022.100834openalex-snapshot

Cross-reactive SARS-CoV-2 epitope targeted across donors informs immunogen design

inferred← citeshttps://doi.org/10.1016/j.xcrm.2022.100910openalex-snapshot

Antibody-dependent cellular cytotoxicity against SARS-CoV-2 Omicron sub-lineages is reduced in convalescent sera regardless of infecting variant

inferred← citeshttps://doi.org/10.1016/j.xcrm.2024.101418openalex-snapshot

An enhanced broad-spectrum peptide inhibits Omicron variants in vivo

inferred← citeshttps://doi.org/10.1016/j.ymthe.2023.09.002openalex-snapshot

Development of AAV-delivered broadly neutralizing anti-human ACE2 antibodies against SARS-CoV-2 variants

inferred← citeshttps://doi.org/10.1016/s0140-6736(21)02844-0openalex-snapshot

Reduced neutralisation of SARS-CoV-2 omicron B.1.1.529 variant by post-immunisation serum

inferred← citeshttps://doi.org/10.1016/s1473-3099(22)00141-4openalex-snapshot

Severity of omicron variant of concern and effectiveness of vaccine boosters against symptomatic disease in Scotland (EAVE II): a national cohort study with nested test-negative design

inferred← citeshttps://doi.org/10.1016/s1473-3099(22)00580-1openalex-snapshot

Neutralisation sensitivity of the SARS-CoV-2 omicron BA.2.75 sublineage

inferred← citeshttps://doi.org/10.1016/s1473-3099(22)00596-5openalex-snapshot

Durability of ChAdOx1 nCoV-19 (AZD1222) vaccine and hybrid humoral immunity against variants including omicron BA.1 and BA.4 6 months after vaccination (COV005): a post-hoc analysis of a randomised, phase 1b–2a trial

inferred← citeshttps://doi.org/10.1016/s1473-3099(23)00199-8openalex-snapshot

Safety, immunogenicity, and efficacy of the mRNA vaccine CS-2034 as a heterologous booster versus homologous booster with BBIBP-CorV in adults aged ≥18 years: a randomised, double-blind, phase 2b trial

inferred← citeshttps://doi.org/10.1016/s2666-5247(22)00222-1openalex-snapshot

Reduced sensitivity of antibody tests after omicron infection

inferred← citeshttps://doi.org/10.1021/acs.jmedchem.3c01201openalex-snapshot

Protective Efficacy of Novel Engineered Human ACE2-Fc Fusion Protein Against Pan-SARS-CoV-2 Infection In Vitro and in Vivo

inferred← citeshttps://doi.org/10.1021/acs.molpharmaceut.4c00165openalex-snapshot

Development of Broad-Spectrum Nanobodies for the Therapy and Diagnosis of SARS-CoV-2 and Its Multiple Variants

inferred← citeshttps://doi.org/10.1038/d41586-021-03824-5openalex-snapshot

Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization

inferred← citeshttps://doi.org/10.1038/s41385-022-00517-8openalex-snapshot

Dealing with a mucosal viral pandemic: lessons from COVID-19 vaccines

inferred← citeshttps://doi.org/10.1038/s41392-022-00997-xopenalex-snapshot

SARS-CoV-2 Omicron variant: recent progress and future perspectives

inferred← citeshttps://doi.org/10.1038/s41392-023-01422-7openalex-snapshot

Comparing T- and B-cell responses to COVID-19 vaccines across varied immune backgrounds

inferred← citeshttps://doi.org/10.1038/s41392-023-01509-1openalex-snapshot

Function and Cryo-EM structures of broadly potent bispecific antibodies against multiple SARS-CoV-2 Omicron sublineages

inferred← citeshttps://doi.org/10.1038/s41421-022-00375-5openalex-snapshot

Reduced sensitivity of SARS-CoV-2 Omicron variant to antibody neutralization elicited by booster vaccination

inferred← citeshttps://doi.org/10.1038/s41421-022-00463-6openalex-snapshot

Combating the SARS-CoV-2 Omicron (BA.1) and BA.2 with potent bispecific antibodies engineered from non-Omicron neutralizing antibodies

inferred← citeshttps://doi.org/10.1038/s41467-022-30340-5openalex-snapshot

Heterologous immunization with inactivated vaccine followed by mRNA-booster elicits strong immunity against SARS-CoV-2 Omicron variant

inferred← citeshttps://doi.org/10.1038/s41467-022-31556-1openalex-snapshot

Neutralization capacity of antibodies elicited through homologous or heterologous infection or vaccination against SARS-CoV-2 VOCs

inferred← citeshttps://doi.org/10.1038/s41467-022-32312-1openalex-snapshot

Lower vaccine-acquired immunity in the elderly population following two-dose BNT162b2 vaccination is alleviated by a third vaccine dose

inferred← citeshttps://doi.org/10.1038/s41467-022-32396-9openalex-snapshot

Omicron BA.4/BA.5 escape neutralizing immunity elicited by BA.1 infection

inferred← citeshttps://doi.org/10.1038/s41467-022-33864-yopenalex-snapshot

Analysis of anti-SARS-CoV-2 Omicron-neutralizing antibody titers in different vaccinated and unvaccinated convalescent plasma sources

inferred← citeshttps://doi.org/10.1038/s41467-022-34280-yopenalex-snapshot

Safety and immunogenicity following a homologous booster dose of CoronaVac in children and adolescents

inferred← citeshttps://doi.org/10.1038/s41467-022-35312-3openalex-snapshot

BA.2 and BA.5 omicron differ immunologically from both BA.1 omicron and pre-omicron variants

inferred← citeshttps://doi.org/10.1038/s41467-022-35642-2openalex-snapshot

Broadly neutralizing and protective nanobodies against SARS-CoV-2 Omicron subvariants BA.1, BA.2, and BA.4/5 and diverse sarbecoviruses

inferred← citeshttps://doi.org/10.1038/s41467-023-36250-4openalex-snapshot

SARS-CoV-2 humoral and cellular immunity following different combinations of vaccination and breakthrough infection

inferred← citeshttps://doi.org/10.1038/s41467-023-36984-1openalex-snapshot

Correlates of protection and viral load trajectories in omicron breakthrough infections in triple vaccinated healthcare workers

inferred← citeshttps://doi.org/10.1038/s41467-023-41049-4openalex-snapshot

Characterizing SARS-CoV-2 neutralization profiles after bivalent boosting using antigenic cartography

inferred← citeshttps://doi.org/10.1038/s41467-023-41678-9openalex-snapshot

Omicron variant neutralizing antibodies following BNT162b2 BA.4/5 versus mRNA-1273 BA.1 bivalent vaccination in patients with end-stage kidney disease

inferred← citeshttps://doi.org/10.1038/s41467-023-44265-0openalex-snapshot

Diverse array of neutralizing antibodies elicited upon Spike Ferritin Nanoparticle vaccination in rhesus macaques

inferred← citeshttps://doi.org/10.1038/s41467-024-48528-2openalex-snapshot

Impacts of human mobility on the citywide transmission dynamics of 18 respiratory viruses in pre- and post-COVID-19 pandemic years

inferred← citeshttps://doi.org/10.1038/s41467-024-52348-9openalex-snapshot

Omicron COVID-19 immune correlates analysis of a third dose of mRNA-1273 in the COVE trial

inferred← citeshttps://doi.org/10.1038/s41541-022-00459-zopenalex-snapshot

Three doses of BNT162b2 vaccine confer neutralising antibody capacity against the SARS-CoV-2 Omicron variant

inferred← citeshttps://doi.org/10.1038/s41541-022-00597-4openalex-snapshot

Challenges and developments in universal vaccine design against SARS-CoV-2 variants

inferred← citeshttps://doi.org/10.1038/s41541-023-00636-8openalex-snapshot

PF-D-Trimer, a protective SARS-CoV-2 subunit vaccine: immunogenicity and application

inferred← citeshttps://doi.org/10.1038/s41541-023-00662-6openalex-snapshot

Interim safety and immunogenicity results from an NDV-based COVID-19 vaccine phase I trial in Mexico

inferred← citeshttps://doi.org/10.1038/s41564-022-01143-7openalex-snapshot

SARS-CoV-2 Omicron is an immune escape variant with an altered cell entry pathway

inferred← citeshttps://doi.org/10.1038/s41565-022-01174-5openalex-snapshot

Nanotechnology-based strategies against SARS-CoV-2 variants

inferred← citeshttps://doi.org/10.1038/s41571-022-00610-8openalex-snapshot

COVID-19 vaccines in patients with cancer: immunogenicity, efficacy and safety

inferred← citeshttps://doi.org/10.1038/s41577-022-00678-4openalex-snapshot

Milder disease with Omicron: is it the virus or the pre-existing immunity?

inferred← citeshttps://doi.org/10.1038/s41586-021-04387-1openalex-snapshot

Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization

inferred← citeshttps://doi.org/10.1038/s41586-022-04399-5openalex-snapshot

Activity of convalescent and vaccine serum against SARS-CoV-2 Omicron

inferred← citeshttps://doi.org/10.1038/s41586-022-04411-yopenalex-snapshot

Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa

inferred← citeshttps://doi.org/10.1038/s41586-022-04830-xopenalex-snapshot

Omicron infection enhances Delta antibody immunity in vaccinated persons

inferred← citeshttps://doi.org/10.1038/s41586-022-04856-1openalex-snapshot

Characterization and antiviral susceptibility of SARS-CoV-2 Omicron BA.2

inferred← citeshttps://doi.org/10.1038/s41586-024-08477-8openalex-snapshot

SARS-CoV-2 evolution on a dynamic immune landscape

inferred← citeshttps://doi.org/10.1038/s41591-022-01739-wopenalex-snapshot

Immune response to SARS-CoV-2 after a booster of mRNA-1273: an open-label phase 2 trial

inferred← citeshttps://doi.org/10.1038/s41591-022-01887-zopenalex-snapshot

Clinical outcomes associated with SARS-CoV-2 Omicron (B.1.1.529) variant and BA.1/BA.1.1 or BA.2 subvariant infection in Southern California

inferred← citeshttps://doi.org/10.1038/s41594-025-01598-2openalex-snapshot

A nanobody-based therapeutic targeting Nipah virus limits viral escape

inferred← citeshttps://doi.org/10.1038/s41598-022-22552-yopenalex-snapshot

Diminished neutralization responses towards SARS-CoV-2 Omicron VoC after mRNA or vector-based COVID-19 vaccinations

inferred← citeshttps://doi.org/10.1038/s41598-023-45517-1openalex-snapshot

Some common deleterious mutations are shared in SARS-CoV-2 genomes from deceased COVID-19 patients across continents

inferred← citeshttps://doi.org/10.1038/s41598-023-45735-7openalex-snapshot

Safety and immunogenicity of the third and fourth doses of vaccine against SARS-CoV-2 following a 2-dose regimen of inactivated whole-virion SARS-CoV-2 vaccine

inferred← citeshttps://doi.org/10.1038/s41598-025-03798-8openalex-snapshot

The presence of neutralizing antibodies against omicron subvariants among a vaccinated cohort at one year after the first dose of vaccination in Malaysia

inferred← citeshttps://doi.org/10.1038/s42003-022-03765-3openalex-snapshot

mRNA booster vaccination protects aged mice against the SARS-CoV-2 Omicron variant

inferred← citeshttps://doi.org/10.1038/s42003-022-03849-0openalex-snapshot

Immune response to SARS-CoV-2 Omicron variant in patients and vaccinees following homologous and heterologous vaccinations

inferred← citeshttps://doi.org/10.1038/s42256-024-00919-2openalex-snapshot

ARNLE model identifies prevalence potential of SARS-CoV-2 variants

inferred← citeshttps://doi.org/10.1038/s43856-022-00174-9openalex-snapshot

Affinity of Anti-Spike Antibodies to Three Major SARS-CoV-2 Variants in Recipients of Three Major Vaccines

inferred← citeshttps://doi.org/10.1038/s43856-025-01093-1openalex-snapshot

A public health perspective of SARS-CoV-2 evolution and surveillance strategies in Germany from 2020 to 2023

inferred← citeshttps://doi.org/10.1038/s43856-026-01647-xopenalex-snapshot

Monitoring viral evolution and epidemiological characteristics of SARS-CoV-2 during 2022–2023 using Integrated Genomic Surveillance

inferred← citeshttps://doi.org/10.1055/a-1987-3682openalex-snapshot

Immune Plasma for the Treatment of COVID-19: Lessons Learned so far

inferred← citeshttps://doi.org/10.1056/nejmc2201607openalex-snapshot

Neutralization Profile after Recovery from SARS-CoV-2 Omicron Infection

inferred← citeshttps://doi.org/10.1056/nejmoa2119658openalex-snapshot

Population Immunity and Covid-19 Severity with Omicron Variant in South Africa

inferred← citeshttps://doi.org/10.1073/pnas.2205784119openalex-snapshot

A broad and potent neutralization epitope in SARS-related coronaviruses

inferred← citeshttps://doi.org/10.1080/07391102.2022.2095305openalex-snapshot

Differences between Omicron SARS-CoV-2 RBD and other variants in their ability to interact with cell receptors and monoclonal antibodies

inferred← citeshttps://doi.org/10.1080/17476348.2023.2210837openalex-snapshot

Pulmonary recovery after COVID-19 – a review

inferred← citeshttps://doi.org/10.1080/21645515.2022.2057161openalex-snapshot

Research progress on vaccine efficacy against SARS-CoV-2 variants of concern

inferred← citeshttps://doi.org/10.1080/22221751.2022.2035195openalex-snapshot

Omicron variant susceptibility to neutralizing antibodies induced in children by natural SARS-CoV-2 infection or COVID-19 vaccine

inferred← citeshttps://doi.org/10.1080/22221751.2024.2412643openalex-snapshot

Neutralisation resistance of SARS-CoV-2 spike-variants is primarily mediated by synergistic receptor binding domain substitutions

inferred← citeshttps://doi.org/10.1080/23744235.2024.2329957openalex-snapshot

Double-blinded, randomised, placebo-controlled trial of convalescent plasma for COVID-19: analyses by neutralising antibodies homologous to recipients’ variants

inferred← citeshttps://doi.org/10.1089/vim.2022.0133openalex-snapshot

A Seroprevalence Study on Residents in a Senior Care Facility with Breakthrough SARS-CoV-2 Omicron Infection

inferred← citeshttps://doi.org/10.1093/cid/ciac203openalex-snapshot

Rapid Spread of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Omicron Subvariant BA.2 in a Single-Source Community Outbreak

inferred← citeshttps://doi.org/10.1093/cid/ciac416openalex-snapshot

Serum Neutralizing Antibody Titers 12 Months After Coronavirus Disease 2019 Messenger RNA Vaccination: Correlation to Clinical Variables in an Adult, US Population

inferred← citeshttps://doi.org/10.1093/cid/ciac435openalex-snapshot

Comparison of Waning Neutralizing Antibody Responses Against the Omicron Variant 6 Months After Natural Severe Acute Respiratory Syndrome Coronavirus 2 Infection (With or Without Subsequent Coronavirus Disease 2019 [COVID-19] Vaccination) Versus 2-Dose COVID-19 Vaccination

inferred← citeshttps://doi.org/10.1093/cid/ciac557openalex-snapshot

Antibody and T-Cell Responses 6 Months After Coronavirus Disease 2019 Messenger RNA-1273 Vaccination in Patients With Chronic Kidney Disease, on Dialysis, or Living With a Kidney Transplant

inferred← citeshttps://doi.org/10.1093/cid/ciac604openalex-snapshot

Protection Against the Omicron Variant Offered by Previous Severe Acute Respiratory Syndrome Coronavirus 2 Infection: A Retrospective Cohort Study

showing the first 200 of 449

Editorial review for independent work. ICSAC — the Institute for Complexity Science and Advanced Computing — runs a structured editorial panel for researchers publishing outside journals, and publishes on CiteStamp rails. Submission is free and goes through ORCID: icsacinstitute.org/submit.